Compare Abbott Laboratories (ABT) vs Schlumberger NV (SLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Schlumberger NV — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Schlumberger NV trades at $47.32 (market cap $69.40B). The key difference: Abbott Laboratories is far larger — about 2.4× Schlumberger NV's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | SLB | |
|---|---|---|
Market Cap | $166.94B | $69.40B |
Sector | Health | Energy |
52-Week High | $136.62 | $58.01 |
52-Week Low | $82.57 | $31.72 |
Enterprise Value | $193.69B | $77.62B |
Dividend Yield | 2.63% | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
SLB trades at $46.42, up 2.86% today, amid a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $0.52, exceeding the $0.508 estimate, and holds a strong analyst consensus with a $63.00 price target. Recent news highlights a seven-year digital innovation contract in Kuwait, expanding its energy technology footprint. Cash flow from operations remains robust at $6.49B for 2025, though net cash flow was negative due to significant financing activities.
The outlook is cautiously optimistic, supported by solid fundamentals and growth initiatives in digital and AI, but faces headwinds from oil price volatility and a recent decline in net income margin to 9.26%. The stock presents a potential opportunity given its valuation discounts to analyst targets, though macroeconomic risks and sector cyclicality warrant attention.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
